四環醫藥(00460.HK)擬成立兩大生物製藥平台總部 逐步剝離仿製藥業務
四環醫藥(00460.HK)公布,擬將整體組織架構設置為集團總部以及業務平台總部的雙組織架構,同時將軒竹生物科技股份及吉林惠升生物製藥兩大生物製藥板塊各自成立業務平台總部。
兩大生物製藥業務平台將在其自身的發展方面擁有更多自主權,亦將能夠更好地利用各自平台總部的專門知識和專攻科目。
公司將繼續向生物製藥業務平台總部提供戰略指導並行使股東權利,會把其管理重心聚焦在成長性更高的業務板塊,以及對仿製藥業務進行優化整合,包括逐步剝離業績不達預期的仿製藥業務,及其他非核心大健康業務,提升營運效率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.